Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
Oral Tolerance Induction in Experimental Autoimmune Encephalomyelitis with Candida utilis Expressing the Immunogenic MOG35-55 Peptide.
Functional Characterization of DNA Methylation in the Oligodendrocyte Lineage.
Transdermal Application of Myelin Peptides in Multiple Sclerosis Treatment.
β-Amyloid: Enemy or Remedy?
Advanced Structural and Functional Brain MRI in Multiple Sclerosis.
Peripheral Bilateral Telangiectasiae in Multiple Sclerosis Patients Treated with Interferon B1a.
PLEGRIDY® (Peginterferon Beta-1a) Three-Year Data Presented at AAN Annual Meeting Support Long-Term Safety and Efficacy in Multiple Sclerosis Patients
Iran mass produces MS drug Ziferon
Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis.
Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus - induced demyelinating disease by modifying Nrf2-Keap1 pathway.
Multiple sclerosis in pregnancy.
Oligodendrogenesis and myelinogenesis during postnatal development effect of glatiramer acetate.
Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis.
Clinical and MRI predictors of response to interferon-beta and glatiramer acetate in relapsing-remitting multiple sclerosis patients.
Alterations in serum MMP-8, MMP-9, IL-12p40 and IL-23 in multiple sclerosis patients treated with interferon-beta1b.
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS.
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.
Posturography in MS patients treated with high dose methylprednisolone.
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
How many injections did you miss last month? A simple question to predict interferon β-1a adherence in multiple sclerosis.
European Medicines Agency, Scientific Discussion of MabCampath (alemtuzumab)
Microcystic macular oedema in multiple sclerosis is associated with disease severity.
Interferon-beta stabilizes barrier characteristics of the blood-brain barrier in four different species in vitro.

Pages